Amarin | AMRN

Stock Price
1.17
Daily Change
0.86%
Yearly
-19.31%
Q2 Forecast
1.15
Rating
Sell

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

API Features Documentation Interested? Click here to contact us
Please Paste this Code in your Website
width
height
 Preview
Peers Price Day Year
AbbVie 137.96 1.52 1.11% -5.52%
Alnylam Pharmaceuticals 185.01 -1.45 -0.78% 50.35%
Amarin 1.17 0.01 0.86% -19.31%
AstraZeneca 11,660.00 162.00 1.41% 11.66%
BioCryst Pharmaceuticals 8.27 0.31 3.89% -12.39%
DBV Technologies 1.95 0.10 5.41% 26.62%
Esperion Therapeutics 1.36 -0.04 -2.86% -74.91%
GlaxoSmithKline 1,346.40 -24.60 -1.79% -21.16%
Halozyme Therapeutics 32.43 -0.42 -1.28% -28.57%
Heron Therapeutics 1.14 -0.05 -4.20% -64.15%
Intercept Pharmaceuticals 10.54 -0.23 -2.14% -40.92%
Ionis Pharmaceuticals 40.90 0.35 0.86% 13.90%
Neurocrine Biosciences 89.53 -0.58 -0.64% -3.47%
Nektar Therapeutics 0.58 -0.04 -6.89% -83.66%
Novartis 87.16 0.14 0.16% 1.14%

Indexes Price Day Year
USND 12935 -82.14 -0.63% 7.84%

Amarin

Amarin traded at $1.17 this Wednesday May 31st, increasing $0.01 or 0.86 percent since the previous trading session. Looking back, over the last four weeks, Amarin gained 15.22 percent. Over the last 12 months, its price fell by 19.31 percent. Looking ahead, we forecast Amarin to be priced at 1.15 by the end of this quarter and at 1.03 in one year, according to Trading Economics global macro models projections and analysts expectations.

Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company operates through the development and commercialization of Vascepa segment. The Company's lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.